References
- Stone M.J. Amyloidosis: a final common pathway for protein deposition in tissues. Blood 1990; 75: 531–545
- Kyle R.A., Gertz M.A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–59
- Tan S.Y., Pepys M.B., Hawkins P.N. Treatment of amyloidosis. Am J Kidney Dis 1995; 26: 267–285
- Gertz M.A., Kyle R.A. Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch lnt Med 1990; 150: 629–633
- Gianni L., Bellotti V., Gianni A., Merlini G. New drug therapy of amyloidoses: resorption of AL type deposits with 4′-iodo-4′-deoxydoxorubicin. Blood 1995; 86: 855–861
- Alexanian R., Dimopoulos M., Delasalle K., Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887–890
- Cooper M.R. Interferons in the management of multiple myeloma. Seminars Oncology 1988; 15: 21–25
- Tanaka H., Tanabe O., Iwato K., Asaouku H., Ishikawa H., Nobuyoshi M. Sensitive inhibitory effect of interferon alpha on M protein secretion of human myeloma cell lines. Blood 1989; 74: 1718–22
- Gertz M.A., Kyle R.A., Greipp P.R. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77: 257–262
- Kyle R.A., Wagoner R.D., Holley R.E. Primary systemic amyloidosis: resolution of nephrotic syndrome with melphalen and prednisone. Arch lnt Med 1982; 142: 1445–50
- Jagannath S., Vesole D., Glenn L., Crowley J., Barlogie B. Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80: 1666–1672
- Skinner M., Anderson J.J., Simms R., Falk R., Wang M., Libbey C.A., Jones L.A., Cohen A.S. Treatment of 100 patients with primary amyloidosis: a randomised trial of melphalan, prednisone and colchicine versus colchicine only. Am J Med 1996; 100: 290–298
- Kyle R.A., Greipp P.R., O'Fallon W.M. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 1986; 68: 220–224
- Gertz M.A., Kyle R.A. Phase II trial of recombinant interferon alfa 2 in the treatment of primary systemic amyloidosis. Am J Hematol 1993; 44: 125–128